This article is more than 5 years old. Information may no longer be current.

Ivantis secures $25 million in funding for commercialization of Hydrus microstent

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Ivantis has secured $25 million in Series C funding for U.S. commercialization of the Hydrus microstent, according to a company press release.

The Hydrus microstent, which is about the size of an eyelash, is expected to be approved by the FDA in 2018, the release said. It is designed to reduce a glaucoma patient’s IOP by re-establishing the natural outflow pathway, which is done through a minimally invasive microsurgical procedure.

RA Capital Management led the financing round, which included an investment from Mérieux Développement and existing investors.